Le Lézard
Classified in: Health
Subject: SVY

Innovations in Pain Management: A Technology Blueprint to Counter Opiod Addiction


LONDON, July 16, 2018 /PRNewswire/ -- Exploring Viable Strategies to Reduce Drug-Device Competitive Initiatives that can Deliver the Right Value of Care for Clinically Safe & Effective Management of Pain Disorders

Download the full report: https://www.reportbuyer.com/product/5474793

Over the past several decades drug therapies for clinically safe and effective management of various types of pain, classified as being acute, chronic, breakthrough, nerve, and bone-related have been treated with the use of opioids, NSAIDS, anticonvulsants and antidepressants.However, increasing reliance on their use for prolonged intervals and side-effects associated with the same have led to an increasing demand for drug-alternatives that can improve or retain quality of life of patients while managing their pain.

Medtech developers have been addressing these concerns over the past two decades with the introduction of device-based pain management therapies.

This research service focuses on the need for replacing opioids and other drug-based therapies for pain control, and underlying implications for various stakeholders involved in enabling the adoption of such therapies for clinically safe and effective management of pain disorders.The research service covers a snapshot of current industry scenario, including coverage of market growth, top players, major drivers and challenges that are challenging the status quo of companies operating across developed and emerging economies.

The chapters also cover gamechanging technologies and research initiatives that drive business performance in competitive portfolios.The research evaluates industry collaborations that are bridging the device-drug gap in treating pain.

A comprehensive analysis of value chain and stakeholder concerns along the value stream is evaluated in-depth through voice of stakeholder approach. The research service evaluates the value of care delivered by drug and device therapies prescribed today for managing pain.

Download the full report: https://www.reportbuyer.com/product/5474793

About Reportbuyer
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +1 (718) 213 4904
Website: www.reportbuyer.com

SOURCE ReportBuyer


These press releases may also interest you

at 14:30
The "Global Immunoprecipitation Testing - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029" report has been added to  ResearchAndMarkets.com's offering. The Global Immunoprecipitation Testing Market size is estimated...

at 14:25
Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and...

at 14:20
Mishe (say "mish-e"), an innovator in direct healthcare, announces the launch of Downstate's Transparent Access Plan, making SUNY Downstate Health Sciences University the first hospital system in the US to offer transparent upfront pricing for its...

at 14:12
Susan G. Komen®, the world's leading breast cancer organization commends the State Assembly's proposed funding increase of $2.5 million for the Cancer Services Program (CSP) in the FY2025 Budget....

at 14:00
Neuroscientists have established in recent decades the idea that some of each day's experiences are converted by the brain into permanent memories during sleep the same night. Now, a new study proposes a mechanism that determines which memories are...

at 14:00
While traditional diaper rash creams are thick, sticky, and messy, Taro's new bébé Bottoms Diaper Rash Crème Spray allows for easy, one-handed application of a gentle spray formula that is touch-free with no rubbing needed. The light spray, which...



News published on and distributed by: